153 related articles for article (PubMed ID: 38212259)
1. Avacincaptad pegol (Izervay) for geographic atrophy in age-related macular degeneration.
Med Lett Drugs Ther; 2024 Jan; 66(1694):15-16. PubMed ID: 38212259
[No Abstract] [Full Text] [Related]
2. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
[TBL] [Abstract][Full Text] [Related]
3. Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration (Ophthalmology. 2021;128:576-586).
Pfau M
Ophthalmology; 2021 Dec; 128(12):e219. PubMed ID: 34600774
[No Abstract] [Full Text] [Related]
4. Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial (Ophthalmology. 2021;128:576-586).
Keenan TDL
Ophthalmology; 2021 May; 128(5):e25-e26. PubMed ID: 33551286
[No Abstract] [Full Text] [Related]
5. Avacincaptad Pegol: First Approval.
Kang C
Drugs; 2023 Oct; 83(15):1447-1453. PubMed ID: 37814173
[TBL] [Abstract][Full Text] [Related]
6. The complement system: a novel therapeutic target for age-related macular degeneration.
Shughoury A; Sevgi DD; Ciulla TA
Expert Opin Pharmacother; 2023; 24(17):1887-1899. PubMed ID: 37691588
[TBL] [Abstract][Full Text] [Related]
7. Pegcetacoplan (Syfovre) for geographic atrophy in age-related macular degeneration.
Med Lett Drugs Ther; 2023 Apr; 65(1673):49-50. PubMed ID: 37020339
[No Abstract] [Full Text] [Related]
8. Piloting a forced-choice task to elicit treatment preferences in geographic atrophy.
Enoch J; Ghulakhszian A; Sekhon M; Crabb DP; Taylor DJ; Dinah C
BMC Res Notes; 2023 Sep; 16(1):244. PubMed ID: 37777762
[TBL] [Abstract][Full Text] [Related]
9. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
[TBL] [Abstract][Full Text] [Related]
10. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS; Lad EM; Holz FG; Rosenfeld PJ; Guymer RH; Boyer D; Grossi F; Baumal CR; Korobelnik JF; Slakter JS; Waheed NK; Metlapally R; Pearce I; Steinle N; Francone AA; Hu A; Lally DR; Deschatelets P; Francois C; Bliss C; Staurenghi G; Monés J; Singh RP; Ribeiro R; Wykoff CC;
Lancet; 2023 Oct; 402(10411):1434-1448. PubMed ID: 37865470
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM; Patel SS; Staurenghi G; Tadayoni R; Danzig CJ; Eichenbaum DA; Hsu J; Wykoff CC; Heier JS; Lally DR; Monés J; Nielsen JS; Sheth VS; Kaiser PK; Clark J; Zhu L; Patel H; Tang J; Desai D; Jaffe GJ;
Lancet; 2023 Oct; 402(10411):1449-1458. PubMed ID: 37696275
[TBL] [Abstract][Full Text] [Related]
12. Geographic atrophy: current and future therapeutic agents and practical considerations for retinal specialists.
Vakharia P; Eichenbaum D
Curr Opin Ophthalmol; 2024 May; 35(3):165-169. PubMed ID: 38421937
[TBL] [Abstract][Full Text] [Related]
13. COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHY: Review of Salient Functional Outcomes and Perspective.
Spaide RF; Vavvas DG
Retina; 2023 Jul; 43(7):1064-1069. PubMed ID: 36996460
[TBL] [Abstract][Full Text] [Related]
14. The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.
Garg A; Nanji K; Tai F; Phillips M; Zeraatkar D; Garg SJ; Sadda SR; Kaiser PK; Guymer RH; Sivaprasad S; Wykoff CC; Chaudhary V
Surv Ophthalmol; 2024; 69(3):349-361. PubMed ID: 38008405
[TBL] [Abstract][Full Text] [Related]
15. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Patel SS; Lally DR; Hsu J; Wykoff CC; Eichenbaum D; Heier JS; Jaffe GJ; Westby K; Desai D; Zhu L; Khanani AM
Eye (Lond); 2023 Dec; 37(17):3551-3557. PubMed ID: 36964259
[TBL] [Abstract][Full Text] [Related]
16. Treatment of dry age-related macular degeneration: A review.
Girgis S; Lee LR
Clin Exp Ophthalmol; 2023 Nov; 51(8):835-852. PubMed ID: 37737509
[TBL] [Abstract][Full Text] [Related]
17. "Izervay (avacincaptad pegol): paving the way for vision preservation in geographic atrophy".
Shakeel L; Khan A; Akilimali A
Ann Med Surg (Lond); 2024 May; 86(5):2413-2416. PubMed ID: 38694318
[TBL] [Abstract][Full Text] [Related]
18. Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study.
Liao DS; Metlapally R; Joshi P
Immunotherapy; 2022 Sep; 14(13):995-1006. PubMed ID: 35860926
[TBL] [Abstract][Full Text] [Related]
19. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
[TBL] [Abstract][Full Text] [Related]
20. Investigational drugs in clinical trials for macular degeneration.
Tolentino MJ; Tolentino AJ
Expert Opin Investig Drugs; 2022 Oct; 31(10):1067-1085. PubMed ID: 35962560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
